Skip to main content
Premium Trial:

Request an Annual Quote

NIH Reissues SBIR, STTR Technology Program for Proteomics, Glycomics

The National Institute of Health has reissued two previous programs under its Small Business Innovation Research and Small Business Technology Transfer program to support technology development for proteomics and glycomics research.
The SBIR and STTR program announcements, available here and here, respectively, are both seeking applications from small businesses propose the development of research tools that address the “core technical challenges” in proteomics and glycomics, including robotics, sample preparation and pre-fractionation, analytical separations, gel and array imaging, quantitation, mass spectrometry, intelligent automated data acquisition, and improved informatics technologies.
NIH said that applicants under both programs can request budgets up to $200,000 per year for up to two years for Phase I awards and budgets up to $400,000 per year for up to four years for Phase II awards.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.